A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies

Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin's lymphoma. Here we describe the proteomic identification of a novel cancer target, SAIL (S...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, S Y, Theunissen, J-W, Balibalos, J, Liao-Chan, S, Babcock, M C, Wong, T, Cairns, B, Gonzalez, D, van der Horst, E H, Perez, M, Levashova, Z, Chinn, L, D‘Alessio, J A, Flory, M, Bermudez, A, Jackson, D Y, Ha, E, Monteon, J, Bruhns, M F, Chen, G, Migone, T-S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476018/
https://www.ncbi.nlm.nih.gov/pubmed/26024286
http://dx.doi.org/10.1038/bcj.2015.39

Ejemplares similares

Ejemplares similares